Literature DB >> 29324302

Addressing the paradox of increasing mastectomy rates in an era of de-escalation of therapy: Communication strategies.

Mona P Tan1, Edibaldo Silva2.   

Abstract

Breast conservation therapy (BCT) was established as the preferred modality of surgical treatment for early stage breast cancer in the early 1990's. Yet, rising mastectomy rates have been observed over the last decade. This increase is a cause for concern as recent large population-based studies have consistently reported improved breast cancer-specific survival and local control rates with BCT, in comparison with mastectomy. There is a pressing need to formulate strategies to effectively inform both patients and practitioners about current data, in the hope of reversing rising mastectomy rates to optimise survival outcomes. Based on the available evidence relating to the motivators for a mastectomy, a format for presenting data to bridge the existing knowledge deficit for effective patient counselling is proposed in this review.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Breast conservation treatment; Communication; Decision-making

Mesh:

Year:  2018        PMID: 29324302     DOI: 10.1016/j.breast.2017.12.010

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  3 in total

1.  The case for breast-conservation treatment rates to be a quality metric.

Authors:  M P Tan; E Silva
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.677

Review 2.  Paradigm shift in the local treatment of breast cancer: mastectomy to breast conservation surgery.

Authors:  Kowsi Murugappan; Apoorva Saboo; Lu Kuo; Owen Ung
Journal:  Gland Surg       Date:  2018-12

3.  A Retrospective Study Assessing the Outcomes of Immediate Prepectoral and Subpectoral Implant and Mesh-Based Breast Reconstruction.

Authors:  Thomas Wow; Agnieszka Kolacinska-Wow; Mateusz Wichtowski; Katarzyna Boguszewska-Byczkiewicz; Zuzanna Nowicka; Katarzyna Ploszka; Karolina Pieszko; Dawid Murawa
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.